ClinicalTrials.gg
Drug

Lisaftoclax clinical trials

Also written APG-2575.

studies test it
32
open now
26
in phase 3
8
first study started
2018

How each study uses Lisaftoclax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Lisaftoclax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lisaftoclax (APG-2575)
8
Lisaftoclax
8

Development codes

APG-2575
9

In one entry with another drug

Given together, or one or the other

Lisaftoclax+daunorubicin+cytarabine
2
Lisaftoclax+homoharringtonine+cytarabine+aclarubicin
2

Studies by the year they started

32 studies that test it; most in 2026 (12)

Studies that test Lisaftoclax, by start year
YearStudies
20181
20191
20203
20215
20222
20231
20244
20253
202612

Who runs them

Industry 16 · Other 16

Ascentage Pharma Group Inc. (16) · Institute of Hematology & Blood Diseases Hospital, China (4) · First Affiliated Hospital of Zhejiang University (2) · Henan Cancer Hospital (2) · Guangdong Second Provincial General Hospital (1) · LanZhou University (1) · Peking University First Hospital (1) · The Affiliated People's Hospital of Ningbo University (1)

Often tested with

Tested in the same studies.

Aclarubicin (2) · Tucidinostat (1) · Olverembatinib (1) · Dexamethasone (1) · Ivosidenib (1) · Venetoclax (1) · Gilteritinib (1) · Homoharringtonine (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6, 2 in phase 3

Studies that test Lisaftoclax, phase 3 first.

Studies

Open first, then newest update. How each study uses Lisaftoclax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 32

See all 32 studies that test Lisaftoclax →

Given beside what is tested · 3 — Lisaftoclax is usual care or a partner of the new treatment

Codes

What other systems call Lisaftoclax · ClinicalTrials.gg INT002005

  • MeSH (NLM) C000726452LisaftoclaxOne source ClinicalTrials.gov
  • UNII (FDA) OSL3FEZ1IFLISAFTOCLAXConfirmed FDA, Wikidata
  • Wikidata Q124721221lisaftoclaxConfirmed FDA, Wikidata
  • NCI Thesaurus C156249LisaftoclaxOne source FDA
  • DrugBank DB18054One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.